Article info

Download PDFPDF

PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes

Authors

  • Stanton A Glantz Department of Medicine/Division of Cardiology, University of California San Francisco, San Francisco, CA 94143-1390, USA Center for Tobacco Control Research and Education, University of California San Francisco, San Francisco, CA 94143-1390, USA PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Stanton A Glantz, Department of Medicine/Cardiology, University of California San Francisco, San Francisco, CA 94143-1390, USA; glantz{at}medicine.ucsf.edu
View Full Text

Citation

Glantz SA
PMI’s own in vivo clinical data on biomarkers of potential harm in Americans show that IQOS is not detectably different from conventional cigarettes

Publication history

  • Received April 4, 2018
  • Revised July 10, 2018
  • Accepted August 1, 2018
  • First published August 21, 2018.
Online issue publication 
October 22, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.